Literature DB >> 33102412

SARS-CoV-2 Infections in the World: An Estimation of the Infected Population and a Measure of How Higher Detection Rates Save Lives.

Carlos Villalobos1.   

Abstract

This paper provides an estimation of the accumulated detection rates and the accumulated number of infected individuals by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Worldwide, on July 20, it has been estimated above 160 million individuals infected by SARS-CoV-2. Moreover, it is found that only about 1 out of 11 infected individuals are detected. In an information context in which population-based seroepidemiological studies are not frequently available, this study shows a parsimonious alternative to provide estimates of the number of SARS-CoV-2 infected individuals. By comparing our estimates with those provided by the population-based seroepidemiological ENE-COVID study in Spain, we confirm the utility of our approach. Then, using a cross-country regression, we investigated if differences in detection rates are associated with differences in the cumulative number of deaths. The hypothesis investigated in this study is that higher levels of detection of SARS-CoV-2 infections can reduce the risk exposure of the susceptible population with a relatively higher risk of death. Our results show that, on average, detecting 5 instead of 35 percent of the infections is associated with multiplying the number of deaths by a factor of about 6. Using this result, we estimated that 120 days after the pandemic outbreak, if the US would have tested with the same intensity as South Korea, about 85,000 out of their 126,000 reported deaths could have been avoided.
Copyright © 2020 Villalobos.

Entities:  

Keywords:  asymptomatic SARS-CoV-2 population; estimates of SARS-CoV-2 infections; infection detection ratio; infection fatality ratio; multiple linear regression

Year:  2020        PMID: 33102412      PMCID: PMC7545403          DOI: 10.3389/fpubh.2020.00489

Source DB:  PubMed          Journal:  Front Public Health        ISSN: 2296-2565


Introduction

Governments and policymakers dealing with the COVID-19 pandemic will fail in their objectives if their actions are guided by misleading data or subsequent misinformation. The authorities should have reliable estimations of the number of SARS-CoV-2 infected individuals. However, there are few attempts to estimate the total amount of infections (1–5). Consequently, health systems face enormous challenges since an unknown and probably a high proportion of all SARS-CoV-2 infections remains undetected. Moreover, data suggest that infected individuals can be highly contagious before the onset of symptoms and SARS-CoV-2 can be also highly contagious in individuals who will never develop any symptoms (6–10). Undetected infections are dangerous because infectious individuals spread the coronavirus in unpredictable ways. Undetected infections consist of non-PCR-tested individuals with symptoms and asymptomatic individuals (non-COVID-19 patients) that are likely to remain undetected over all phases of the infection. However, non-PCR-tested individuals with symptoms would tend to auto-select themselves, depending on the severity of their symptoms (from mild to severe), toward treatment and late detection. For this reason, it is important to know the proportion of the infected population which is asymptomatic or has such mild symptoms that self-select them into the group of non-PCR-tested individuals (11–15). Here, regarding the estimation of the number of infections, and for purposes of public health, I advocate the view by Amartya Sen and Martha Nussbaum that is preferable to be vaguely right than precisely wrong. The public health problem is that undetected asymptomatic individuals, as well as late-detected SARS-CoV-2 infected individuals, increase the risk for vulnerable groups. Since there is a transmission channel between the level of detection and the number of deaths, the early detection of asymptomatic infections, pre-symptomatic, and mild COVID-19 cases is a public health concern. Moreover, undetected cases also are responsible for the collapse of the health system by numerous aggravated and sometimes unexpected COVID-19 patients requiring treatment in a short period. Overwhelmed health care systems reduce the recovery prospects of patients by the lack of treatment, undertreatment, increased risk of mistreatment of all patients, including those with COVID-19, and also put at unnecessarily risk the health workforce (21, 22). The problem is that many governments formulate their strategies and responses to the pandemic based on figures that they can control. This problem of reverse causality produces contra-productive incentives for governments since public opinion tends to negatively react to the report of the cumulative and the marginal numbers of detected (reported) cases. The contradiction is that something good, such as the increase in the testing efforts by governments can be perceived by the public opinion as something bad (due to the increase in detections). Worldwide, the media communicates confirmed cases and deaths as the relevant parameters to take into consideration when assessing the evolution of the pandemic. This is a mistake since this emphasis discourages governments from decidedly pushing for mass testing with the obvious consequence of an increased number of detected cases (although, as shown in this paper, there is a theoretical mechanism relating more testing with saving lives). More sophisticated observers would use the crude and adjusted case fatality ratios to assess the pandemic evolution. However, international comparisons show that crude and adjusted case fatality ratios are highly heterogeneous and their use can be misleading (23, 24). For instance, the simple division of the cumulative number of deaths by the cumulative number of confirmed cases underestimated the true case fatality ratio in past epidemics (24, 25). Although nowadays many case fatality ratios have been estimated in this pandemic correcting many of the observed past biases (26–28), they are still depending on testing efforts made by countries. The problem with heterogeneous case fatality ratios (different proportions of all cases that will end in death due to methodological differences on the denominator) is that they are not anchored at any exogenous information that allows researchers to perform international or territorial comparisons based on credible, and transparent assumptions. Consequently, to rely on the number of confirmed cases makes international comparations impossible since governments have shown to implement highly heterogeneous SARS-CoV-2 testing strategies ending up in different levels of location-based under-ascertainment. In an attempt to solve the mentioned problem, we anchor our analysis in the cumulative number of deaths, which is a statistic much more difficult to alter, in free societies, than the number of SARS-CoV-2 tests. We use this information together with the newest and sound estimates of the age-stratified infection fatality ratios (IFRs) provided in the recent SARS-CoV-2 related literature. In particular, we base our analysis on the IFR of 0.657% reported in Verity et al. (26). This IFR is very close to the 0.75% reported in a meta-analysis of 13 IFR estimates from a wide range of countries, and that were published between February and April of 2020 (30). We also assume orthogonal attack rates of the infection which is also supported by recent literature (16). By weighting the age-stratified IFRs by the country population age-groups shares in each country, it is possible to obtain country-specific IFRs. The relevance of this study is 3-fold: Firstly, the estimation of the true number of infections includes not only confirmed cases but COVID-19 undetected cases, as well as SARS-CoV-2-infected individuals without the disease, or in a pre-symptomatic stage. Therefore, to provide an estimation of the true number of SARS-CoV-2 infections is of more utility than to be only informed about the number of confirmed infections. This is because confirmed cases depend on the testing efforts that can be altered or even manipulated by governments. Moreover, one can compare the true estimate of infections with the number of COVID-19 patients that require hospitalization. Such ratios can contribute to predicting, with exogenous-to-government information, shortages of the health systems. Secondly, the estimation of the true number of SARS-CoV-2 infections allows us to estimate the detection rate of the infection, which is a measure of the performance of health systems and governments while facing the pandemic. One can expect that higher levels of detection of SARS-CoV-2 infections, which includes asymptomatic population, and those in their early stages of the infection (which are more infectious) can reduce the risk exposure of the susceptible population with relatively a high risk of death, that is, the elderly and those individuals with preexisting conditions (17). Accordingly, a highly neglected statistic, such as the detection rate should be considered highly relevant from the public health point of view. Thirdly, in this paper, we test the hypothesis that higher detection rates can save lives while providing a measure of this impact (having in mind that is preferable to be vaguely right than precisely wrong). Thus, this study aims to quantify the importance of testing while providing empirical support to the utility of implementing massive SARS-CoV-2 tests. Overall, this study argues that it is crucial to compute the evolution of the cumulative number of estimated SARS-CoV-2 infected individuals, and subsequently, the cumulative detection rates. This information would provide public health managers and governments the incentives to improve detection rates, rather than to the opposite. Moreover, the identification strategy can be used at lower levels of aggregation, such as regions, provinces, and municipalities to improve responses to the pandemic, including the planning of selective lockdowns or spatial-selective enhancements of the installed critical care units. In summary, this study proposes a baseline estimation of the number of SARS-CoV-2 infections and detection rates based on current information and transparent assumptions. However, the assumptions discussed later in this paper can be later modified to match the current scientific available evidence and country-specific developments and contexts.

Data and Methods

Data

For this research, we use the cumulative number of deaths and confirmed cases in the world and by country, published by OurWorldInData.org, a project of the Global Change Data Lab with the collaboration of the Oxford Martin Programme on Global Development at the University of Oxford. Age-stratified demographic proportions of the population were obtained from the UN population data. The age-stratified IFRs are those reported in Verity et al. (26). Our method also requires to know the distribution of the number of days between infection and death. Since this number is unknown, we approach to this number using the sum of the median incubation period as reported in Lauer et al. (31), and the mean number of days between the onset of symptoms and death as reported in Verity et al. (26). For our empirical exercise, we rely on World Development data by the World Bank (GDP per capita and health expenditure as a share of the GDP) and in World Health Organization data for BCG vaccination. In this study, our regression analysis relies on data for 91 countries covering above 86% of the world population. The remaining countries were excluded because they either do not have significant mortality figures (for instance Uruguay, Monaco, Bermuda, etc.), or full data.

Methods

Estimation Strategy

In this study, we rely on a very simple rationale. At a given point in time, the cumulative number of deaths should be a proportion of the cumulative number of infections somewhat in the past. But how many days in the past? The answer lies in the sum of the number of days of incubation and the number of days between the onset of symptoms and death. This rationale follows a report focusing on the 40 most-affected countries by the pandemic in the world (32). However, in this paper, we deviated from the mentioned report by using the key parameters in a different way, which translated into a different estimation of the number of infected individuals. On average, deaths occur ~18 days (17.8 days with 95% credible interval [CrI] 16.9–19.2) after the onset of COVID-19 symptoms (26), while the incubation period of COVID-19 has been estimated in about 5 days (5.1 days with 95% CI, 4.5–5.8) as reported in Lauer et al. (31). Thus, by comparing the cumulative number of deaths at time t in country i (cdeaths() with the country-specific infection fatality ratio (ifr), which is assumed constant over time, it is possible to obtain a rough approximation of the cumulative number of SARS-CoV-2 infections 23 days (18 days + 5 days) in the past (cinfected(). Additionally, we use the ratio between the cumulative number confirmed (detected) cases at time t−23 in country i (cconfirmed() and the cumulative number of infected individuals (cinfected() at time t−23 in country i as a rough measure of the cumulative rate of detection of SARS-CoV-2 infections at time t−23.

Infection Fatality Ratio

In order to estimate the country-specific infection fatality ratio for country i used in equation 1, we weight the age-stratified infection fatality ratios reported in Verity et al. (26), by the age-group population shares of country i. The calculation of the age-stratified infection fatality ratios relies on two assumptions that can be modified when producing point estimates of the number of individuals affected by a SARS-CoV-2 infection. Firstly, it assumes that there are no cross-country differences in the average overall health status of the population, comorbidity, or in the soundness of the different health systems. In absence of standardized country-specific information of these variables, this assumption is convenient although, at first sight, it can be considered a restrictive one. However, it is quite the opposite since, in richer countries with higher proportions of elderly populations, the estimated infection mortality ratios are likely to be overestimated. If so, our estimates of the infected population represent a lower limit of the true number of infections. The second assumption is that the attack rate of the coronavirus is unrelated to the age and sex of susceptible individuals. This is in concordance with the evidence in respiratory infections in previous pandemic processes (26, 33). Then, the distribution of IFRs across countries reflects the “fixed” lethality of the virus associated to a varying demographic structure of the population across the world. Figure 1 presents the calculated infection fatality ratios for the world, and for 50 countries in which the lethality of the pandemic has been more significant.
Figure 1

Infection fatality ratios (selected countries, in percentage). Source: Own elaboration.

Infection fatality ratios (selected countries, in percentage). Source: Own elaboration. Recently, a cross-sectional epidemiological study with a super-spreading event in the county of Heinsberg in Germany offered the opportunity to estimate the infection fatality ratio in the community (34). The estimated infection fatality ratio was 0.36%. Although this number is surprisingly low when compared with other estimations, for instance, the used in this study for Germany (1.3%), it is not evident that the true infection fatality ratio is closer to 0.36% rather than 1.3%. This is because there can be local factors that explain the discrepancy as pointed out in the Heinsberg study. Amongst these factors, it might be mentioned comorbidity gaps, ethnic differences, the quality and coverage of the health systems, climatic differences, immunization levels, etc.. Consequently, it might be necessary to assess the consequences of using an overestimated infection fatality ratio (that is, an IFR closer to the one reported in the Heinsberg study, or others inferred from seroprevalence data (36). The answer is that the number of infections would be underestimated, and that detection rates would be overestimated (since the infection fatality ratio is on the denominator). An overestimation of the detection rates reduces the validity of international rankings based on this figure. However, from the public health point of view, this would be irrelevant since, as discussed later, all countries should increase their detection rates of SARS-CoV-2 infections as much as possible.

Regression Analysis

To investigate whether improving the detection rates of SARS-CoV-2 infections is potentially associated to save lives, we use a parsimonious synchronic cross-country multiple linear regression. That is, we use the information reported 15, 60, and 105 days after the confirmation of the first 100 SARS-CoV-2 infections, which corresponds to the pandemic outbreak (PO). At a given pandemic phase, we regress the natural logarithm of the cumulative number of deaths in country i, ln(deaths), on their estimated detection rates (DR) and its squared to assess whether there is a non-linear relationship of this conditional correlation. The four parsimonious regressions have a demographic control that corresponds to the estimated country-specific infection fatality ratio (ifr). This is a non-endogenous control since it only captures the impact of demography (population shares by age-groups) on the number of deaths and not the reverse. The regressions control for the population size of the country i in its natural logarithmic form ln(pop). This control is necessary because the share of the susceptible population remains persistently at relatively higher levels in more populated countries when compared with the less populated ones. We also include the natural logarithm of the number of confirmed SARS-CoV-2 infections in each country ln(confirmed). This is a measure of the persistence of the mortality process while controlling for cross-country differences in their absolute testing performances. The regressions also control for the economic performance of a country by means of the natural logarithm of the per capita gross domestic product ln(gdppc). We also include the current health expenditure as share of GDP in 2017 (healthshare). This control is needed to account for relative resource-dependent differences in the coverage/quality of the health systems around the globe. Finally, we use available data to explore a possible association between BCG vaccination and aggravated cases of COVID-19, and deaths [a relationship which is being investigated in some clinical trials (37)]. The evidence is still inconclusive because the argued existence of uncontrolled confounders (38–42). However, if these confounders exist, they can bias the relationship between SARS-CoV-2 detections rates and the cumulative number of deaths. Based on this argument, we include a raw of dummies capturing the degree of BCG vaccination coverage as follows: BGC group 1: no mandatory vaccination (up to 49.9% coverage), BGC group 2: 50 to 79.9% coverage, BGC group 3: 80 to 89.9%, BGC group 4: 90 to 98.9%, and BGC group 5: 99 to 100%. The reference category is BCG group 1.

Robustness

An alternative approach is used to indirectly investigate the conditional association between detection rates and SARS-CoV-2 related deaths. Instead of using the detection rates and its square, we use the natural logarithm of the estimated number of infections ln(infections) while dropping from the equation the natural logarithm of the number of confirmed (detected) SARS-CoV-2 infections as follows: Regarding the statistical inference, significance tests rely on a heteroscedasticity consistent covariance matrix (HCCM) type HC3 which is suitable when the number of observations is small (43). Although in the presence of heteroscedasticity of unknown form, Ordinary Least Square estimates are unbiased, the inference can be misleading due to the fact that the usual tests of significance are generally inappropriate (43). Additionally, we estimate the same set of equations (the main specification and the robustness specification 15, 60, and 105 days after the pandemic outbreak) using robust regressions. We do this because we have the concern that parameter estimates may be biased if, in some countries (outliers), the report of the cumulative number of deaths has been involuntarily altered or even manipulated. Robust regression resists the effect of such outliers, providing better than OLS efficiency when heavy-tailored error distributions exist as it can be likely the case (44).

Results

Descriptive Analysis

On July 20, the estimated infected population reaches about 160 million individuals (Figure 2A). This number is about 19 times larger than the reported number of confirmed cases (about 8.6 million represented by the dashed line). Note that the number of infections is estimated based on detection rates calculated 23 days in the past. Thus, for the period t−23 to t, the number of SARS-CoV-2 infected individuals are estimated using the estimation rate as in t−23. Therefore, the estimation of SARS-CoV-2 infected individuals can be biased if detection rates deteriorate or improve considerably within this time span.
Figure 2

Estimates of the number of SARS-CoV-2 infections and the estimated detection rate in the World. (A) Estimated and confirmed infected population. (B) Estimated Global detection rate. Note that (B) depicts the detection rates until t−23. Both panels display 95% confidence intervals. Source: Own elaboration.

Estimates of the number of SARS-CoV-2 infections and the estimated detection rate in the World. (A) Estimated and confirmed infected population. (B) Estimated Global detection rate. Note that (B) depicts the detection rates until t−23. Both panels display 95% confidence intervals. Source: Own elaboration. The accuracy of our estimations can be assessed by contrasting them against to those provided by population-based seroepidemiological studies. There are some studies of this type focusing on restricted geographical areas, for instance, in Germany and Switzerland (34, 45). However, to the best of our knowledge, there is only one country level and large scale population-based seroepidemiological study performed in Spain (46). The ENE-COVID study in Spain finds that, on 11 May, 5% of the population would test IgG positive against SARS-CoV-2. It implies that about 2.35 million individuals were infected by SARS-CoV-2. Similarly, in our study we estimated on 11 May an infected population of about 2.25 million individuals. This evidence suggests that our method can be a suitable alternative when population-based seroepidemiological studies are not available, which is frequently the case. Here, it is important to recognize that, from the public health point of view, it is preferable to be vaguely right than precisely wrong. On 11 May, Spain confirmed only 246,504 cases (about 10% of all estimated infections). At that time, it would have been convenient that public health authorities and the public opinion would have the information that, for each confirmed case, there were significantly much more individuals spreading the infection in unpredictable ways. Back to the global estimates, by comparing the cumulative number of estimated infections with the cumulative number of confirmed (detected) cases, we obtain, at the end of June 2020, a global detection rate of about 9% (Figure 2B). The global detection rate curve shows an U-shape with a minimum at the beginning of the third week of March reaching only 1.1%. The last data suggest that detection rates are steadily increasing. Moreover, the semi-logarithmic plot in Figure 2A suggests that the infection stopped spreading at its maximum pace approximately during the third week of March, but unfortunately, it increased its speed again around the last week of June. The world distribution of the number of deaths, the estimated number of SARS-CoV-2 infections, and the detection rates of SARS-CoV-2 infections across the world are displayed in Figures 3–5, respectively.
Figure 3

World distribution of deaths as of 20 July 2020. Source: Own Elaboration.

Figure 5

World distribution of the estimated detection rates of SARS-CoV-2 infections as of 20 July 2020 (in percentage). Source: Own Elaboration.

World distribution of deaths as of 20 July 2020. Source: Own Elaboration. World distribution of the estimated number of SARS-CoV-2 infections as of 20 July 2020. Source: Own Elaboration. World distribution of the estimated detection rates of SARS-CoV-2 infections as of 20 July 2020 (in percentage). Source: Own Elaboration. Since the global estimates are no more than an aggregation of the trajectories made by the different countries in the world, we investigate how heterogeneous the detection rates across countries are. Table 1 presents this information in a synchronic way. The rankings compare countries in the same phase of their respective pandemic processes, that is after 15, 30, 45, 60, 75, and 90 days after the confirmation of the first 100 SARS-CoV-2 infections (pandemic outbreak). This approach allows us to perform such an international comparison.
Table 1A

Synchronic descriptive statistics (15, 30, and 45 days after the pandemic outbreak).

Country/Days since the first 100 cases were confirmedDetection rankingsConfirmed Cases (in thousands)Estimated Cases (in thousands)Estimated detection rate (Percentage)Number of deaths (Count)
153045153045153045153045153045
South Korea1236.38.810.215.822.525.339.839.140.442103183
Australia2111.86.06.76.79.710.427.361.164.174574
Luxembourg3672.23.43.89.311.212.323.330.030.9236990
Thailand4321.42.62.96.06.97.023.037.841.774154
Lithuania55120.81.31.43.44.15.423.032.426.393646
Croatia612131.01.82.14.57.48.322.624.425.373677
Estonia7880.61.31.63.44.75.518.727.930.112550
Norway8761.75.57.110.219.222.717.028.731.2750154
Finland924231.02.84.57.218.424.013.315.018.6448186
Israel10453.010.715.424.233.139.012.532.539.510101199
Czech R.1110112.15.77.416.622.727.212.425.327.19119218
Japan1221300.41.03.73.46.824.212.115.415.163673
Greece1315180.92.02.57.810.812.311.418.720.32690130
Chile1413242.47.914.921.738.785.511.320.517.4892216
Austria1511103.612.314.833.450.454.410.924.427.316220463
Bosnia & H.1631330.71.31.96.111.915.110.811.012.9244879
Albania1718170.40.60.83.63.63.910.416.821.6222631
Slovenia1825280.61.21.46.38.28.810.114.516.095082
Bulgaria1930310.50.81.64.77.711.09.811.014.5104172
Puerto Rico2026220.81.42.38.110.311.69.813.319.44284113
Cuba2119190.61.41.87.38.48.88.516.320.2165477
Malaysia2216161.54.05.518.322.524.78.317.622.4146393
Tunisia2329370.60.91.07.28.18.78.211.111.8223844
Serbia24941.25.79.414.720.923.28.027.340.331110189
Portugal2514144.316.023.954.180.594.57.919.825.376470903
Suriname260.33.97.88
Switzerland2717204.820.227.775.8119.4137.76.416.920.1435401,134
Moldova2835391.02.64.515.426.939.96.39.711.21973143
South Africa2951581.42.66.022.352.4121.06.25.04.9548116
Ukraine3023211.77.614.228.450.672.05.915.119.752193361
Nicaragua31391.12.019.824.45.68.34664
Macedonia3233420.51.21.58.711.614.95.610.610.2175486
Denmark3328261.55.17.927.239.747.25.412.816.824203384
El Salvador3441340.20.71.74.78.714.05.08.012.381533
Libya35530.40.78.316.54.74.2518
Panama3636361.34.06.728.543.956.64.69.211.932109192
Poland3734321.66.711.935.767.390.44.69.913.218232562
Argentina3847511.12.74.727.644.769.64.15.96.734122237
Bangladesh3943452.910.926.773.0151.7297.24.07.29.0101183386
Russia402792.324.5106.560.6188.2370.03.913.028.8171981,073
Guatemala4166790.40.93.110.233.4123.43.82.72.5112455
China42202514.470.680.3383.7455.1473.83.815.516.93041,7712,946
Romania4338401.56.311.341.475.9104.73.58.310.829306631
Turkey44322915.774.2122.4471.0677.4786.33.311.015.62771,6433,258
Saudi Arabia4544271.24.920.138.674.0124.33.26.716.2865152
Germany4622153.857.3125.1123.2374.0545.73.115.322.984552,969
Haiti4737380.52.54.717.529.040.83.08.611.5214882
Ireland4846412.49.719.681.9159.7187.42.96.010.5363341,102
Morocco4942351.03.05.234.839.642.62.97.712.370143191
South Sudan5040430.31.31.912.016.418.72.88.010.161434
Dominican R.5149461.64.78.257.983.798.72.75.68.377226346
Canada5245483.420.743.9125.1340.8552.52.76.17.9355092,302
Hungary5352530.71.93.025.538.645.92.75.06.632189351
Colombia5456551.13.27.040.279.5130.02.64.15.417144314
Niger5577810.60.80.926.736.637.72.42.12.4193655
Pakistan5664621.66.015.871.6203.6377.32.32.94.218107346
U. Arab E.5748440.75.412.529.591.6128.42.35.99.7633105
Sweden5860561.66.414.477.9197.1287.12.13.35.0163731,540
Ecuador5974642.37.924.9118.0359.2652.62.02.23.879388900
Somalia6061610.61.42.031.843.846.91.93.14.2285578
Bolivia6171680.41.13.119.746.592.41.82.33.42855142
Burkina Faso6276800.40.60.725.529.530.71.62.12.4234148
Honduras6387760.40.72.024.844.470.71.61.52.82561116
Iraq6462730.51.41.836.344.661.21.53.13.0427888
Sierra Leone6563670.30.81.123.026.030.41.53.03.6204550
Kenya6686850.20.40.816.127.445.71.51.51.8112150
Cameroon6773770.81.82.857.182.5107.31.42.22.61259136
D. R. Congo6879710.30.61.419.331.142.01.41.83.3223161
Algeria6972701.32.74.8102.5122.5147.81.32.23.3152384470
Mauritania7059650.72.24.553.464.6120.31.33.43.73195129
Netherlands7154503.016.632.7239.8395.9482.81.24.26.81061,6513,684
Iran7268599.029.468.2733.61,167.91,440.01.22.54.73542,2344,232
Mali7385860.40.71.130.946.363.51.21.51.7213867
Chad7480840.50.80.941.243.543.51.21.82.0506573
Afghanistan7583740.61.54.748.896.5159.41.11.62.91857122
Peru7658541.111.537.0106.5319.1627.91.03.65.9302541,051
Sudan7784820.82.75.580.1177.8234.91.01.52.345111314
Philippines7867691.14.67.8118.9177.0234.00.92.63.368297511
Brazil7981833.922.266.5433.61,333.93,175.90.91.72.11141,2234,543
Indonesia8075721.34.69.5148.1215.2307.20.92.13.1114399773
Italy8155527.463.9135.6899.61,566.62,024.00.84.16.73666,07717,129
Spain8250479.294.4181.51,205.51,865.52,182.40.85.18.33098,18918,893
India8369661.311.433.1164.6456.0899.40.82.53.7323771,074
Egypt8482780.62.25.077.0136.9203.10.71.62.536164359
Belgium8565572.318.438.5316.7634.0770.70.72.95.0371,2835,683
Nigeria8688750.31.55.054.2111.0175.10.61.42.81044164
France8770604.540.298.1742.31,732.22,149.80.62.34.6912,60614,967
Mexico8889871.46.320.7251.9691.81,525.60.50.91.4374861,972
U.K.8978633.338.2114.2907.21,904.72,945.90.42.03.91443,60515,464
U.S.9057494.7189.6639.71,547.15,216.88,058.60.33.67.9854,07930,985
Yemen9190880.30.71.1126.8170.9242.10.20.40.566160302

This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.

Synchronic descriptive statistics (15, 30, and 45 days after the pandemic outbreak). This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration. Synchronic descriptive statistics (60, 75, and 90 days after the pandemic outbreak). This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration. At a first sight, it is noteworthy the fact that each of the first 24 countries ranked on the top by the initial detection rate (15 days after the beginning of the pandemic outbreak) does not accumulate more than 500 deaths 45 days after initiating their pandemic processes. Thus, it seems to exist a strong correlation between detection rates and the cumulative number of deaths for a given stage of the pandemic process. Countries with high counts of deaths ranked very badly in their initial detection rates. For example, the US, Spain, Italy, UK, France, and Belgium ranked in place 90, 82, 81, 89, 87, and 85, out of 91 countries listed in the ranking. A second conclusion is that the relative improvement of detection rates over time, that is, 30, 45, 60, 75, and 90 days after the beginning of the pandemic processes, does not alter the fact that those countries are still ranked the worst in terms of deaths. That is, improving detection over time has declining returns to scale when comes to save lives. The depicted relationship between detection rates and the cumulative number of deaths remains almost unchanged when using non-synchronic data as of 20 May in Table 2. This table mixes information of countries at different stages from their pandemic processes. So, it must be interpreted with caution. Although efforts to increase detection have been significative in the above-mentioned countries, none of them is still ranked on the top part of the ranking with 91 countries for which we have full data (US in ranking 36, Spain 45, Italy 46, Belgium 55, UK 56, and France in place 58). Similarly, in this non-synchronic ranking, with the exception of Russia, none of the first 10 countries accumulated more than 500 deaths on May 20.
Table 2

Non-synchronic descriptive statistics as of 20 May.

CountryDetection rate rankingConfirmed CasesEstimated CasesNumber of DeathsDetection rate (Percentage)CountryDetection rate rankingConfirmed CasesEstimated CasesNumber of DeathsDetection rate (Percentage)
Australia17,06810,8039965.4Macedonia471,83920,6291068.9
Serbia210,73324,47223443.9Bangladesh4825,121284,7583708.8
Russia3299,941713,3962,83742.0Peru4999,4831,137,3092,9148.7
Thailand43,0347,2935641.6Netherlands5044,249529,5815,7158.4
Israel516,65042,23927739.4Argentina518,796114,0043937.7
South Korea611,11028,75726338.6Sweden5230,799417,2343,7437.4
Norway78,25724,04123334.3Hungary533,59850,2654707.2
Luxembourg83,95812,36810932.0Colombia5416,935256,1496136.6
Estonia91,7915,8916430.4Belgium5555,791847,6769,1086.6
Czech R.108,64730,10530228.7U.K.56248,8183,792,37135,3416.6
Japan1116,38557,45577128.5Iran57124,6031,992,7407,1196.3
Austria1216,25758,59963227.7France58143,4272,444,44128,0225.9
Malaysia136,97826,05611426.8Pakistan5945,898844,1029855.4
Germany14176,007671,7168,09026.2India60106,7502,054,5853,3035.2
Portugal1529,432113,9591,24725.8South Africa6117,200363,4753124.7
Lithuania161,5626,0606025.8Philippines6212,942287,9238374.5
Croatia172,2328,7639625.5Libya63681,54434.4
Finland186,39926,03630124.6Ecuador6434,151784,1372,8394.4
Puerto Rico192,80511,95112423.5Algeria657,377173,8475614.2
Albania209494,0883123.2Brazil66271,6286,890,82617,9713.9
Ukraine2118,87686,90554821.7Bolivia674,481115,3421893.9
Denmark2211,04452,13455121.2Indonesia6818,496480,8001,2213.8
Cuba231,8878,9267921.1D. R. Congo691,73147,886613.6
Greece242,84013,67116520.8Somalia701,50244,338593.4
Switzerland2530,535147,7941,61320.7South Sudan712858,42163.4
Saudi Arabia2659,854303,50132919.7Egypt7213,484401,8286593.4
Turkey27151,615862,9114,19917.6Honduras732,95588,8241473.3
Poland2819,268114,17094816.9Afghanistan747,653230,9111783.3
U. Arab E.2925,063150,49622716.7Nigeria756,401203,5101923.1
Bulgaria302,29214,22711616.1Cameroon763,529113,1181403.1
Slovenia311,4679,20610415.9Haiti7759619,339223.1
Morocco327,02344,48119315.8Burkina Faso7880630,682522.6
Bosnia & H.332,31915,81313314.7Suriname791142912.6
Chile3449,579359,51450913.8Niger8091437,746552.4
Romania3517,191125,6401,12613.7Sierra Leone8153424,508332.2
U.S.361,528,56811,884,24491,92112.9Guatemala822,133103,309432.1
Panama379,86777,34928112.8Kenya8396349,412501.9
China3884,065667,7024,63812.6Iraq843,611199,7791311.8
Moldova396,34051,91222112.2Mexico8554,3463,289,7905,6661.7
Ireland4024,251203,1281,56111.9Mali8690157,558531.6
Tunisia411,0448,8654711.8Sudan872,591169,5751051.5
El Salvador421,49812,9053111.6Chad8854542,352561.3
Dominican R.4313,223116,83644111.3Mauritania898127,36140.3
Canada4479,101763,8895,91210.4Yemen9016767,359280.2
Spain45232,5552,247,53327,88810.3Nicaragua912514,73980.2
Italy46226,6992,472,70332,1699.2

Countries are ranked by the detection rates of SARS-CoV-2 infections as of 20 May. Source: Own elaboration.

Non-synchronic descriptive statistics as of 20 May. Countries are ranked by the detection rates of SARS-CoV-2 infections as of 20 May. Source: Own elaboration. In Table 3, we present the non-synchronic ranking as of 22 June. The US is in place 35, Spain 49, Italy 53, Belgium 63, UK 61, and France 67. It is noteworthy that, except for Russia, none of the first 16 countries in this ranking have accumulated more than 2,000 fatalities on 22 June. More importantly and despite the incredible efforts to increase the tests amongst the more developed countries, none of them were able to detect more than 16% of the estimated infections (the US detected 15.7% on 22 June). It implies that testing efforts need to be deployed at the first stages of the pandemic process due to its cumulative nature. Tables 2, 3 show that moving over time from relatively low to relatively high cumulative detection rates is unlikely and probably very expensive. This is due to the over proportional efforts needed to expand testing relative to the exponentially growing infections at the early stages of the pandemic. Consequently, from the public health point of view, it is much more advantageous, technically, and economically feasible, to implement mass testing from the very beginning of the pandemic process. To achieve this goal, health authorities and governments would require understanding the linkages between the cumulative detection rates and the minimization of the pandemic related fatalities and economic damage.
Table 3

Non-synchronic descriptive statistics as of 22 June.

CountryDetection rate rankingConfirmed CasesEstimated CasesNumber of DeathsDetection rate (Percentage)CountryDetection rate rankingConfirmed CasesEstimated CasesNumber of DeathsDetection rate (Percentage)
Australia17,46111,47810265.0Sweden4756,043479,2325,05311.7
Russia2584,6801,271,0528,11146.0Peru48254,9362,272,4068,04511.2
Puerto Rico36,52514,52114944.9Spain49246,5042,357,97828,32410.5
Thailand43,1487,3015843.1Macedonia505,10649,13323810.4
South Korea512,43830,17628041.2South Sudan511,88218,6883410.1
Israel620,77851,83530640.1Pakistan52181,0881,908,4273,5909.5
Norway78,70825,09824434.7Italy53238,4992,533,48134,6349.4
Estonia81,9815,8966933.6Netherlands5449,593538,8686,0909.2
Serbia912,89438,73526133.3El Salvador554,62653,3271078.7
Luxembourg104,12012,50811032.9Brazil561,085,03812,484,11850,6178.4
Czech R.1110,49832,66633632.1Nicaragua572,01424,386648.3
Malaysia128,57227,04012131.7South Africa5897,3021,269,3751,9307.7
Portugal1339,133127,8641,53030.6Hungary594,10254,2815727.6
Japan1417,91661,66595329.1Suriname603144,17087.5
Austria1517,28561,81769028.0U.K.61304,3314,151,85142,6327.3
Lithuania161,7986,4977627.7India62425,2826,033,05713,6997.0
Germany17190,359699,1548,88527.2Belgium6360,550861,9769,6967.0
Finland187,14326,40232627.1Philippines6430,052438,0381,1696.9
U. Arab E.1944,925178,15530225.2Iran65204,9523,050,0489,6236.7
Cuba202,3129,2818524.9Colombia6668,6521,030,6952,2376.7
Ukraine2136,560148,3761,00224.6France67160,3772,515,34429,6406.4
Chile22242,355991,3364,47924.4D. R. Congo685,82698,9161305.9
Croatia232,3179,95710723.3Cameroon6911,610199,0803015.8
Denmark2412,39153,63860023.1Bolivia7024,388424,5227735.7
Greece253,26614,53319022.5Somalia712,77949,186905.7
Poland2631,931150,5821,35621.2Afghanistan7228,833565,2465815.1
Switzerland2731,209148,9121,68021.0Indonesia7345,891905,2572,4655.1
Saudi Arabia28157,612823,6391,26719.1Nigeria7420,244409,3275184.9
Turkey29187,685984,3584,95019.1Honduras7512,769263,0323634.9
Morocco309,97755,38621418.0Algeria7611,771242,6458454.9
Albania311,92711,3004417.1Egypt7755,2331,182,3382,1934.7
Bulgaria323,90523,58619916.6Ecuador7850,6401,084,6414,2234.7
Bangladesh33112,306678,7671,46416.5Kenya794,738109,8291234.3
Slovenia341,5209,41010916.2Libya8054412,846104.2
U.S.352,280,91214,248,772119,97515.7Sierra Leone811,32731,692554.2
Moldova3614,20093,47047315.2Mauritania822,81375,6871083.7
Bosnia & H.373,35422,22516915.1Guatemala8313,145398,0785313.3
Panama3826,030180,81950114.4Sudan848,580276,7285213.1
Argentina3942,772303,3411,01114.1Burkina Faso8590330,773532.9
Romania4024,045177,7751,51213.5Mali861,96173,3061112.7
Dominican R.4126,677197,25166213.5Niger871,03639,912672.6
Tunisia421,1579,1445012.7Mexico88180,5457,666,94521,8252.4
China4384,572668,5644,63912.6Chad8985843,988742.0
Ireland4425,379208,3661,71512.2Iraq9030,8681,582,9721,1002.0
Canada45101,326845,1498,43012.0Yemen91941203,7322560.5
Haiti465,21144,0658811.8

Countries are ranked by the detection rates of SARS-CoV-2 infections as of 22 June. Source: Own elaboration.

Non-synchronic descriptive statistics as of 22 June. Countries are ranked by the detection rates of SARS-CoV-2 infections as of 22 June. Source: Own elaboration.

Unconditional Analysis

In this analysis, we show the unconditional relationship between detection rates and deaths. The fitted lines in Figure 6 are obtained after regressing the natural logarithm of the cumulative number of deaths in the country i on their estimated cumulative detection rates (DR). The results strongly suggest a negative relationship between detection rates and the cumulative number of deaths. This strong negative slope is in concordance with the hypothesis that, by detecting a higher proportion of the SARS-CoV-2 infected population, many lives can be saved, in particular, the lives of the elderly and those individuals with preexisting conditions.
Figure 6

Linear prediction for the natural logarithm of the cumulative number of deaths from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the pandemic outbreak (PO). (A) Detection rates and deaths 15 days after the PO. (B) Detection rates and deaths 120 days after the PO. (A) contains all 91 countries (in Table 1A). (B) contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the PO. The dashed fitted line excludes South Korea (KR). Source: Own elaboration.

Linear prediction for the natural logarithm of the cumulative number of deaths from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the pandemic outbreak (PO). (A) Detection rates and deaths 15 days after the PO. (B) Detection rates and deaths 120 days after the PO. (A) contains all 91 countries (in Table 1A). (B) contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the PO. The dashed fitted line excludes South Korea (KR). Source: Own elaboration. The strong association between the number of deaths and the estimated cumulative detection rates remains significant 15, and 120 days after the PO. These associations are shown in Figures 6A,B, respectively. Figure 7 shows the relationship between detection rates (15 and 120 days after the PO) and deaths 120 days after the PO. This descriptive result is of interest since it suggests that, unconditionally, early detection is associated with death outcomes 120 days after the PO to a greater extent than the contemporary detection rates, that is, 120 days after the PO.
Figure 7

Linear prediction for the natural logarithm of the cumulative number of deaths 120 days after the pandemic outbreak (PO) from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the PO. (A) Deaths reported 120 days after the PO, and detection rates estimated 15 days after the PO. (B) Deaths reported 120 days after the PO, and detection rates 120 days after the PO. Note: This figure contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the pandemic outbreak. Source: Own elaboration.

Linear prediction for the natural logarithm of the cumulative number of deaths 120 days after the pandemic outbreak (PO) from a linear regression of ln(deaths) on the detection rates (DR) 15 and 120 days after the PO. (A) Deaths reported 120 days after the PO, and detection rates estimated 15 days after the PO. (B) Deaths reported 120 days after the PO, and detection rates 120 days after the PO. Note: This figure contains all 61 countries (in Table 1A) whose pandemic processes have more than 120 days since the pandemic outbreak. Source: Own elaboration. Although this information suggests the existence of a strong relationship between detection rates and the cumulative number of deaths, this slope may be confounded by the variables mentioned before. Thus, in the next section, we show the results of our conditional analysis as described earlier.

Multivariate Regression Analysis

Our results in Table 4 show that higher detection rates are associated with a reduction in the number of deaths after controlling for demography (age-structure of the population and population size), economic performance (GDP per capita), and the relative resources that the economies devote to their health systems. Over time, the cross-sectional regressions increase in explanatory power, from a R-squared of 0.71 in model 2 to 0.95 in model 8.
Table 4

Synchronic multiple linear regression of the natural logarithm of the cumulative number of deaths on the estimated detections rates.

Dependent Variable: Ln(deaths)/Explanatory VariablesDays since the first 100 cases were confirmed
1560120
Model (1)Model (2)Model (3)Model (4)Model (5)Model (6)Model (7)Model (8)
Estimated detection rate−0.193***−0.225***−0.120***−0.118***−0.100***−0.0976***
(0.0358)(0.0269)(0.0368)(0.0435)(0.0220)(0.0217)
Estimated detection rate (Squared)0.00410***0.00497***0.001350.001320.000948*0.000931*
(0.00127)(0.000698)(0.000919)(0.00107)(0.000501)(0.000484)
Estimated detection rate 15 days after PO−22.30***−16.78***
(6.266)(5.479)
Estimated detection rate 15 days after PO (squared)47.64*35.63
(28.54)(24.01)
Infection fatality rate0.960***0.922***1.586***1.512***1.396***1.525***1.506***1.439***
(0.333)(0.328)(0.267)(0.270)(0.370)(0.172)(0.179)(0.329)
Population size (Ln)−0.150**−0.146**−0.0285−0.01790.01050.0699**0.0649*0.0267
(0.0656)(0.0688)(0.0856)(0.0780)(0.0787)(0.0345)(0.0356)(0.0518)
Confirmed cases (Ln)0.860***0.773***0.943***0.910***0.705***0.931***0.929***0.849***
(0.0995)(0.108)(0.0696)(0.0640)(0.0796)(0.0324)(0.0334)(0.0639)
GDP per capita (Ln)−0.446***−0.417***0.03990.05700.07420.181***0.168**−0.0194
(0.108)(0.103)(0.0842)(0.0913)(0.138)(0.0600)(0.0642)(0.154)
Health spending as % of GDP−0.0570*−0.0552−0.0147−0.0270−0.0009550.00186−0.01150.00210
(0.0330)(0.0354)(0.0231)(0.0260)(0.0277)(0.0143)(0.0163)(0.0312)
BCG group 2−0.4410.1750.1240.185*0.196
(0.323)(0.161)(0.206)(0.101)(0.233)
BCG group 3−0.3960.0449−0.01850.1850.197
(0.284)(0.235)(0.305)(0.165)(0.332)
BCG group 4−0.704***−0.193−0.205−0.0324−0.131
(0.220)(0.184)(0.209)(0.102)(0.213)
BCG group 5−0.411*−0.172−0.1750.02000.0653
(0.210)(0.152)(0.176)(0.0856)(0.178)
Constant4.530***5.355***−2.365−2.204−1.313−5.437***−5.174***−2.425*
(1.391)(1.434)(1.431)(1.442)(1.629)(0.679)(0.776)(1.362)
Observations8787848484747474
R-squared0.6720.7080.9500.9540.9340.9840.9850.954
R-squared adjusted0.6430.6660.9450.9470.9240.9830.9830.946
F-test2621.86342.3274.9110.5594.5404.1137.8

Standard errors in parentheses. Significance levels:

p < 0.01,

p < 0.05,

p < 0.1. Source: Own elaboration.

Synchronic multiple linear regression of the natural logarithm of the cumulative number of deaths on the estimated detections rates. Standard errors in parentheses. Significance levels: p < 0.01, p < 0.05, p < 0.1. Source: Own elaboration. Based on these results, Figure 8 shows a strong conditional gradient between detection rates and the cumulative number of deaths. For instance, for a hypothetical country with average and constant endowments, the cost in terms of deaths of detecting 5% vs. 35% is about 1.81 natural logarithm points which corresponds to exp1.81 = 6.13. That is, the average country detecting 5% is associated with a number of deaths about 6.1 times higher when compared with the same country detecting 35% of all SARS-CoV-2 infections.
Figure 8

Predictive Margins of the cumulative number of deaths at different detection rates of SARS-CoV-2 infections after 120 days of the pandemic outbreak. Source: Own elaboration.

Predictive Margins of the cumulative number of deaths at different detection rates of SARS-CoV-2 infections after 120 days of the pandemic outbreak. Source: Own elaboration. To put this result in perspective, let us simulate what would be the number of deaths in the U.S., if instead of detecting 16.02% 120 days after the pandemic outbreak, the country would have detected with the same intensity as South Korea (41.01%). Evaluating the number of deaths at the endowments of the U.S, the country would have fewer deaths by 1.14 natural logarithm points. It means that the current U.S deaths are now 3.13 times higher than they would be if the country would have tested with similar intensity as South Korea. Since the number of deaths 120 days after the pandemic outbreak reached 126,140, detecting at the rate of South Korea would have saved about 85,794 lives in the U.S. at that time. Finally, looking at the regression coefficients in Table 3, it is noteworthy the fact that during the pandemic outbreak, a 1% higher detection rate is associated with more lives saved than a 1% increase in the health expenditure over the GDP. Our results also suggest that the number of deaths, rather than depending on the relative solvency of the health system, could depend in a greater extent on the size and opportunity of the testing efforts. The conclusion is the more tests the better. Although in this study we employed an economics inspired approach to figure out the importance of testing, our findings are also endorsed by recent medical literature on coronavirus as well as by another economics inspired models providing support to a causal relationship between detection and saving lives (47–50).

Robustness of the Results

Robust regressions provide estimates that are close to the ones reported in Table 4. Consequently, it is unlikely that the results reported in this study are outlier driven. Additionally, results are robust to heteroscedasticity of unknown form for small samples. Nevertheless, results should be interpreted with caution. The few observations available for the regressions and lack of data does not allow to rule out the possibility that there are omitted variables that have the potential to bias the results. It is important to keep in mind that results can be biased if omitted variable problem exists. That is, there are variables that are correlated with the explained outcome but at the same time they are also correlated with the explanatory variables of interest. For instance, one can think in countries implementing lockdowns because lower detection rates (Argentina), or relaxed social distancing rules because higher detection rates (Australia). Nevertheless, these non-observed variables yield to an underestimation of the true association between detection rates and the cumulative number of deaths. Thus, detection matters.

Discussion

In this study, we have proposed a method to estimate the number of SARS-CoV-2 infections for the globe and also for all 91 major countries covering more than 86% of the world population. On June 22, we find that, worldwide, about 160 million individuals have been infected by SARS-CoV-2. Moreover, only about 1 out of 11 these infections have been detected. We find that detection rates are very unequally distributed across the globe and that they also increased over time from about 1% during the second and third weeks of March to about 9% on June 22. In an information context in which population-based seroepidemiological studies are not available, this study shows a parsimonious alternative to provide estimates of the number of SARS-CoV-2 infected individuals. By comparing our estimates with those provided by the ENE-COVID study in Spain, we confirm the utility of our approach keeping in mind that from the public health point of view, it is preferable to be vaguely right than precisely wrong. In order to provide reliable estimates of the number of SARS-CoV-2 infections and of the cumulative detection rates, it is necessary that governments provide real-time information about the number of COVID-19 deaths. This study supports the view that an accurate communication of the fatality cases can have consequences on the development of the pandemic itself. Thus, it is also a call for allowing international comparison following WHO international norms and standards for medical certificates of COVID-19 cause of death and International Classification of Diseases (ICD) mortality coding. Additionally, in our empirical analysis, we have presented parsimonious evidence, that higher detection rates are associated with saving lives. Our conditional analysis shows, for example, that if the US would have had the same detection rate trajectory as South Korea, about two-thirds of the reported deaths could have been avoided (about 85,000 lives). We find that detection rates at the very early stages of the pandemic seem to explain the great divergence in terms of deaths between countries. Moreover, we showed evidence that moving from relatively low to high cumulative detection rates (and thus saving lives) is unlikely and difficult. This is probably due to the high level of efforts needed to expand testing relative to the exponentially growing infections at the early and middle stages of the pandemic. Thus, from the public health point of view, it is better to deploy testing efforts at the first stages of the pandemic process. To do this would be much more advantageous, in terms of saved lives, but also it would be technically, and economically feasible. Already, many developed countries with well-developed health sectors were not able to avoid unnecessary deaths by their inaction in terms of promoting mass testing to counter the pandemic outbreak at early stages. To achieve the goal of implementing mass testing from the very beginning of the pandemic outbreak, governments need to understand the consequences of not doing that. Thus, the evidence presented in this paper offers a rigorous macro-level linkage between detection rates and the cumulative number of deaths which may be useful in future pandemics. This evidence also supports the implementation of mass testing in the likely coming secondary pandemic outbreak (so-called second waves). Further research should be devoted to understanding why the detection capacity in many advanced countries was too weak, late, and also so weakly correlated (if correlated) with the income levels. In this paper, we claim that governments have incentives against test because the public opinion tends to primarily react to the report of the cumulative and the marginal numbers of detected (reported) cases. The contradiction is that something good, such as the increase in the testing efforts by governments, can be perceived by the general public as something negative (due to the increase in detections). In consequence, are low detection rates in developed countries simply a management failure, or are there long-run incentives that promoted this behavior among many rich countries? It is clear that during the ongoing pandemic, improving detection rates is a race against time, but are there institutional and/or technological constraints that hamper detection improvements that can save lives? All these questions are relevant for this and future pandemics. This study claims that all countries in the world should be able to respond to a pandemic outbreak with massive testing in the very short run. This would be an efficient approach since it is also likely that higher detection rates are also associated with a lesser impact of the pandemic on the economy.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author Contributions

CV conceived this research, performed the background work, collected the data, performed all statistical analyses, and wrote the paper.

Conflict of Interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Table 1B

Synchronic descriptive statistics (60, 75, and 90 days after the pandemic outbreak).

Country/Days since the first 100 cases were confirmedDetection rankingsConfirmed Cases (in thousands)Estimated Cases (in thousands)Estimated detection rate (Percentage)Number of deaths (Count)
607590607590607590607590607590
South Korea67610.710.811.126.927.928.839.738.738.6236254263
Australia1116.97.17.310.810.811.063.865.765.997101102
Luxembourg89103.94.04.112.412.412.431.732.532.9104110110
Thailand3443.03.13.17.37.37.341.442.042.9565758
Lithuania1416151.61.71.86.16.46.525.826.427.6607176
Croatia1618222.22.22.38.88.89.525.425.423.795103107
Estonia91091.71.82.05.95.95.929.631.233.4616669
Norway7887.88.38.423.324.024.733.634.334.1208233237
Finland1919176.06.67.025.626.126.323.325.326.7267308324
Israel56516.516.818.441.042.745.940.339.340.0258281299
Czech R.1011128.19.09.829.630.532.127.529.530.4280317328
Japan13121411.115.416.442.854.557.626.028.228.5186543777
Greece2425242.72.93.113.414.014.320.320.621.3151172183
Chile27332737.090.6167.4209.2608.1866.717.714.919.33589443,101
Austria12131615.716.316.858.158.961.026.927.727.5608633672
Bosnia & H.3534362.32.63.316.017.621.714.614.715.1135158168
Albania2026311.01.21.94.26.411.123.018.917.0313343
Slovenia3132331.51.51.59.19.29.416.016.015.9102106109
Bulgaria3335342.22.53.514.117.722.215.814.215.6110144181
Puerto Rico11533.35.36.912.212.815.327.241.744.9129143151
Cuba2220192.02.22.39.09.19.321.724.224.9828385
Malaysia1515116.57.18.325.426.726.725.526.731.1107115117
Tunisia4143421.01.11.28.99.09.111.812.012.7474950
Serbia22710.611.412.424.325.534.243.744.836.4230244256
Portugal17141327.731.035.6109.6115.5121.125.226.929.41,1441,3421,495
Switzerland23242529.930.530.8145.4147.8148.420.620.720.81,4761,6131,659
Moldova3938356.79.214.055.173.489.812.212.615.5233323464
South Africa64605514.432.773.5304.5592.71,015.74.75.57.22616831,568
Ukraine21212120.627.037.291.7119.4151.122.422.624.66057881,012
Macedonia4851471.92.64.820.933.846.68.97.710.3110147222
Denmark25222310.111.211.950.252.553.220.121.422.4514561587
El Salvador46492.94.631.153.39.48.753107
Panama3737379.413.521.473.699.2151.612.813.614.1269336448
Poland30292616.922.528.2105.0125.4142.116.117.919.88391,0281,215
Argentina5245407.817.434.1106.9161.7254.47.310.813.4366556878
Bangladesh38313257.6105.5159.7460.1638.5965.112.516.516.57811,3881,997
Russia432262.8396.6529.0639.9896.21,146.141.144.246.22,4184,5556,948
Guatemala78767.113.8239.1417.03.03.3252547
China29404381.182.483.8480.8667.4667.616.912.312.53,2413,3164,636
Romania36364115.818.621.2119.2136.2158.913.213.713.31,0021,2191,369
Turkey282828148.1163.9179.8853.5906.0956.917.318.118.84,0964,5404,825
Saudi Arabia26273044.880.2119.9227.4435.6678.519.718.417.7273441893
Germany181718157.6172.2180.5626.6662.7680.825.226.026.56,1157,7238,450
Haiti406.151.611.8110
Ireland42424423.224.825.2198.5204.4207.711.712.112.21,4881,6311,703
Morocco3230297.18.09.644.746.452.716.017.318.2194208213
Dominican R.43413913.218.024.6116.8148.3183.311.312.213.4441516635
Canada45444567.784.796.2700.1784.8820.99.710.811.74,6936,4247,835
Hungary5352533.63.94.150.152.453.97.17.57.6467534568
Colombia54546014.929.453.1233.8429.7809.26.46.86.65629391,726
Niger81801.01.038.939.52.52.66567
Pakistan60625237.266.5139.2686.11,230.31,658.45.45.48.48031,3952,632
U. Arab E.34232021.833.942.3145.2159.4171.515.021.324.7210262289
Sweden55535022.730.840.8365.8417.2457.66.27.48.92,7693,7434,542
Ecuador70717131.538.646.8763.3890.21,027.24.14.34.62,5943,3343,896
Somalia57592.62.948.051.85.55.78890
Bolivia6261658.416.930.7160.1310.3534.05.25.55.7293559970
Burkina Faso8078740.80.90.930.730.730.92.72.92.9525353
Honduras6774684.47.415.4103.6182.8316.54.24.04.9188290426
Iraq8282763.05.517.8124.6442.81,081.12.41.21.6115179496
Sierra Leone681.433.34.259
Kenya7973722.03.76.468.790.8147.62.94.14.364104148
Cameroon7364645.49.212.6158.6173.4215.93.45.35.8177273313
D. R. Congo6563633.04.86.966.689.8117.84.55.35.969106167
Algeria6669697.59.811.5176.2209.3237.24.34.74.9568681825
Netherlands51505140.844.246.7514.4529.6534.87.98.48.75,0825,7155,977
Iran59576189.3107.6137.71,638.31,843.72,132.35.55.86.55,6506,6407,451
Mali83791.62.069.474.82.32.794112
Chad840.944.42.074
Afghanistan71676611.822.130.2296.0443.9591.64.05.05.1220405675
Peru49464684.5155.7229.71,017.41,497.72,038.98.310.411.32,3934,3716,688
Sudan75778.39.7266.9311.73.13.1506604
Philippines69685811.415.024.2273.5314.0358.54.24.86.77519041,036
Brazil766654177.6411.8802.85,729.28,243.910,800.03.15.07.412,40025,59840,919
Indonesia72727015.424.536.4425.5583.9762.33.64.24.81,0281,4962,048
Italy504849187.3215.9228.72,287.72,412.92,485.68.28.99.225,08529,95832,616
Spain474748215.2230.7239.42,381.42,247.52,345.99.010.310.224,82427,56327,127
India63655982.0173.8320.91,675.23,312.04,874.14.95.26.62,6494,9719,195
Egypt77757310.420.841.3340.3614.6975.53.13.44.25568451,422
Belgium56555750.355.858.7823.7847.7857.36.16.66.87,9249,1089,522
Nigeria7470678.915.224.1266.1339.2486.83.44.54.9259399558
France615862126.8140.7149.12,350.22,424.92,468.35.45.86.023,66027,07428,662
Mexico85817547.190.7150.32,899.64,823.56,766.91.61.92.25,0459,93017,580
U.K.585656186.6246.4278.03,403.73,778.53,971.65.56.57.028,44634,79639,369
U.S.4439381,069.81,443.41,770.410,137.111,539.112,571.510.612.514.163,00687,568103,781

This ranking is made up of all countries with more than 30 deaths due to COVID-19 40 days after the pandemic outbreak. Countries are ranked by their detection rates 15 days after the pandemic outbreak. Missing values in this table indicate that the country has not reached the requested number of days after its pandemic outbreak. Source: Own elaboration.

  36 in total

1.  Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection.

Authors:  J Xu; Y Li; F Gan; Y Du; Y Yao
Journal:  J Dent Res       Date:  2020-04-09       Impact factor: 6.116

2.  Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.

Authors:  Seth Flaxman; Swapnil Mishra; Axel Gandy; H Juliette T Unwin; Thomas A Mellan; Helen Coupland; Charles Whittaker; Harrison Zhu; Tresnia Berah; Jeffrey W Eaton; Mélodie Monod; Azra C Ghani; Christl A Donnelly; Steven Riley; Michaela A C Vollmer; Neil M Ferguson; Lucy C Okell; Samir Bhatt
Journal:  Nature       Date:  2020-06-08       Impact factor: 49.962

3.  Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies.

Authors:  Hanalise V Huff; Avantika Singh
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

4.  Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).

Authors:  Fang Jiang; Liehua Deng; Liangqing Zhang; Yin Cai; Chi Wai Cheung; Zhengyuan Xia
Journal:  J Gen Intern Med       Date:  2020-03-04       Impact factor: 5.128

Review 5.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

Authors:  Yan-Rong Guo; Qing-Dong Cao; Zhong-Si Hong; Yuan-Yang Tan; Shou-Deng Chen; Hong-Jun Jin; Kai-Sen Tan; De-Yun Wang; Yan Yan
Journal:  Mil Med Res       Date:  2020-03-13

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

7.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.

Authors:  Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous
Journal:  Lancet       Date:  2020-06-11       Impact factor: 79.321

8.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).

Authors:  Ruiyun Li; Sen Pei; Bin Chen; Yimeng Song; Tao Zhang; Wan Yang; Jeffrey Shaman
Journal:  Science       Date:  2020-03-16       Impact factor: 47.728

9.  Serial interval of novel coronavirus (COVID-19) infections.

Authors:  Hiroshi Nishiura; Natalie M Linton; Andrei R Akhmetzhanov
Journal:  Int J Infect Dis       Date:  2020-03-04       Impact factor: 3.623

10.  A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates.

Authors:  Gideon Meyerowitz-Katz; Lea Merone
Journal:  Int J Infect Dis       Date:  2020-09-29       Impact factor: 3.623

View more
  4 in total

Review 1.  Advanced Molecular and Immunological Diagnostic Methods to Detect SARS-CoV-2 Infection.

Authors:  John Charles Rotondo; Fernanda Martini; Martina Maritati; Elisabetta Caselli; Carla Enrica Gallenga; Matteo Guarino; Roberto De Giorgio; Chiara Mazziotta; Maria Letizia Tramarin; Giada Badiale; Mauro Tognon; Carlo Contini
Journal:  Microorganisms       Date:  2022-06-10

2.  Evaluation of the number of undiagnosed infected in an outbreak using source of infection measurements.

Authors:  Akiva Bruno Melka; Yoram Louzoun
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

3.  Predictors of COVID-19 Fatality: A Worldwide Analysis of the Pandemic over Time and in Latin America.

Authors:  Dayana Rojas; Jorge Saavedra; Mariya Petrova; Yue Pan; José Szapocznik
Journal:  J Epidemiol Glob Health       Date:  2022-01-14

4.  A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population.

Authors:  Stefano Mocci; Roberto Littera; Stefania Tranquilli; Aldesia Provenzano; Alessia Mascia; Federica Cannas; Sara Lai; Erika Giuressi; Luchino Chessa; Goffredo Angioni; Marcello Campagna; Davide Firinu; Maria Del Zompo; Giorgio La Nasa; Andrea Perra; Sabrina Giglio
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.